口分田 貴裕 (クモデ タカヒロ)

  • 医学科 医学部講師
Last Updated :2024/04/23

コミュニケーション情報 byコメンテータガイド

  • コメント

    白血病や悪性リンパ腫など造血管腫瘍、造血幹細胞移植を専門とする。

研究者情報

学位

  • 博士(医学)(2022年03月 近畿大学)

ホームページURL

J-Global ID

研究キーワード

  • 悪性リンパ腫   血小板   造血幹細胞   造血器腫瘍   

現在の研究分野(キーワード)

    白血病や悪性リンパ腫など造血管腫瘍、造血幹細胞移植を専門とする。

研究分野

  • ライフサイエンス / 血液、腫瘍内科学

経歴

  • - 現在  近畿大学医学部血液・膠原病内科医学部講師

学歴

  • - 現在   近畿大学   医学部

所属学協会

  • 日本輸血・細胞治療学会   日本臨床腫瘍学会   日本リンパ網内系学会   日本造血細胞移植学会   日本血液学会   日本内科学会   

研究活動情報

論文

  • Takahiro Haeno; Shinya Rai; Yoshiaki Miyake; Maiko Inoue; Ko Fujimoto; Aki Fujii; Yoshio Iwata; Shuji Minamoto; Takahide Taniguchi; Hiroaki Kakutani; Hiroaki Inoue; Takahiro Kumode; Kentaro Serizawa; Yasuhiro Taniguchi; Chikara Hirase; Yasuyoshi Morita; Hirokazu Tanaka; Yoichi Tatsumi; Takashi Ashida; Itaru Matsumura
    Journal of clinical and experimental hematopathology : JCEH 63 2 99 - 107 2023年06月 
    We retrospectively evaluated long-term outcomes of high dose chemotherapy followed by autologous stem cell transplant (HDC/ASCT) in patients with diffuse large B-cell lymphoma (DLBCL). Between 2004 and 2020, 46 DLBCL patients received HDC/ASCT in our institution, including 12 patients (26.1%), who received as an upfront setting (UFS). At a median follow-up time of 69 months (range, 2-169 months), the 5-year progression-free survival (PFS) rates were 82.5% (95%CI, 46.1-95.3%) in the UFS, and 57.8% (95%CI, 38.1-73.2%) in the relapsed or refractory (R/R) patients (n=34), respectively. The 5-year PFS rates were 62.3% (95%CI, 34.0-81.3%) in primary resistant (n=13) or early relapsing (within 1 year from the initial diagnosis) patients (n=4), and 53.3% (95%CI, 25.9-74.6%) in those relapsing >1 year after the initial diagnosis (n=17), with no statistically significant difference (p=0.498). In R/R patients, multivariate analysis showed that the remission status before HDC/ASCT was an independent poor prognostic factor for progression-free survival (hazard ratio [HR], 17.0; 95%CI, 3.35-86.6; p=0.000630) and high-risk category in the international prognostic index for OS (HR, 9.39; 95%CI, 1.71-51.6; p=0.0100). The incidence of non-relapse mortality by 5 years, and 10 years were 12.2%, and 15.2%, respectively. Eleven patients (23.9%) developed second malignancies, which was the most frequent late complication after HDC/ASCT, with 5-year, and 10-year cumulative incidence of 16.9%, 22.5%, respectively. In conclusion, HDC/ASCT is effective for chemo-sensitive R/R DLBCL regardless of the timing and lines of therapy. However, careful observation is required, considering the long-term complications such as secondary malignancies.
  • 口分田 貴裕
    血液内科 = Hematology / 血液内科編集委員会 編 85 4 581 - 585 科学評論社 2022年10月
  • Ryosuke Fujiwara; Yasuhiro Taniguchi; Shinya Rai; Yoshio Iwata; Aki Fujii; Ko Fujimoto; Takahiro Kumode; Kentaro Serizawa; Yasuyoshi Morita; J Luis Espinoza; Hirokazu Tanaka; Hitoshi Hanamoto; Itaru Matsumura
    Biochemical and biophysical research communications 626 156 - 166 2022年08月 
    We previously reported that the antipsychotic drug chlorpromazine (CPZ), which inhibits the formation of clathrin-coated vesicles (CCVs) essential for endocytosis and intracellular transport of receptor tyrosine kinase (RTK), inhibits the growth/survival of acute myeloid leukemia cells with mutated RTK (KIT D816V or FLT3-ITD) by perturbing the intracellular localization of these molecules. Here, we examined whether these findings are applicable to epidermal growth factor receptor (EGFR). CPZ dose-dependently inhibited the growth/survival of the non-small cell lung cancer (NSCLC) cell line, PC9 harboring an EGFR-activating (EGFR exon 19 deletion). In addition, CPZ not only suppressed the growth/survival of gefitinib (GEF)-resistant PC9ZD cells harboring T790 M, but also restored their sensitivities to GEF. Furthermore, CPZ overcame GEF resistance caused by Met amplification in HCC827GR cells. As for the mechanism of CPZ-induced growth suppression, we found that although CPZ hardly influenced the phosphorylation of EGFR, it effectively reduced the phosphorylation of ERK and AKT. When utilized in combination with trametinib (a MEK inhibitor), dabrafenib (an RAF inhibitor), and everolimus (an mTOR inhibitor), CPZ suppressed the growth of PC9ZD cells cooperatively with everolimus but not with trametinib or dabrafenib. Immunofluorescent staining revealed that EGFR shows a perinuclear pattern and was intensely colocalized with the late endosome marker, Rab11. However, after CPZ treatment, EGFR was unevenly distributed in the cells, and colocalization with the early endosome marker Rab5 and EEA1 became more apparent, indicating that CPZ disrupted the intracellular transport of EGFR. These results suggest that CPZ has therapeutic potential for NSCLC with mutated EGFR by a novel mechanism different from conventional TKIs alone or in combination with other agents.
  • Takahiro Kumode; Hirokazu Tanaka; Jorge Luis Esipinoza; Shinya Rai; Yasuhiro Taniguchi; Ryosuke Fujiwara; Keigo Sano; Kentaro Serizawa; Yoshio Iwata; Yasuyoshi Morita; Itaru Matsumura
    International journal of hematology 115 3 310 - 321 2022年03月 
    C-type lectin-like receptor 2 (CLEC-2) expressed on megakaryocytes plays important roles in megakaryopoiesis. We found that CLEC-2 was expressed in about 20% of phenotypical long-term hematopoietic stem cells (LT-HSCs), which expressed lower levels of HSC-specific genes and produced larger amounts of megakaryocyte-related molecules than CLEC-2low LT-HSCs. Although CLEC-2high LT-HSCs had immature clonogenic activity, cultured CLEC-2high LT-HSCs preferentially differentiated into megakaryocytes. CLEC-2high HSCs yielded 6.8 times more megakaryocyte progenitors (MkPs) and 6.0 times more platelets 2 weeks and 1 week after transplantation compared with CLEC-2low LT-HSCs. However, platelet yield from CLEC-2high HSCs gradually declined with the loss of MkPs, while CLEC-2low HSCs self-renewed long-term, indicating that CLEC-2high LT-HSCs mainly contribute to early megakaryopoiesis. Treatment with pI:C and LPS increased the proportion of CLEC-2high LT-HSCs within LT-HSCs. Almost all CLEC-2low LT-HSCs were in the G0 phase and barely responded to pI:C. In contrast, 54% of CLEC-2high LT-HSCs were in G0, and pI:C treatment obliged CLEC-2high LT-HSCs to enter the cell cycle and differentiate into megakaryocytes, indicating that CLEC-2high LT-HSCs are primed for cell cycle entry and rapidly yield platelets in response to inflammatory stress. In conclusion, CLEC-2high LT-HSCs appear to act as a reserve for emergent platelet production under stress conditions.
  • Kentaro Serizawa; Hirokazu Tanaka; Takeshi Ueda; Ayano Fukui; Hiroaki Kakutani; Takahide Taniguchi; Hiroaki Inoue; Takahiro Kumode; Yasuhiro Taniguchi; Shinya Rai; Chikara Hirase; Yasuyoshi Morita; J. Luis Espinoza; Yoichi Tatsumi; Takashi Ashida; Itaru Matsumura
    International Journal of Hematology 115 3 336 - 349 2022年03月
  • Shinya Rai; Hiroaki Inoue; Kazuko Sakai; Hitoshi Hanamoto; Mitsuhiro Matsuda; Yasuhiro Maeda; Takahiro Haeno; Yosaku Watatani; Takahiro Kumode; Kentaro Serizawa; Yasuhiro Taniguchi; Chikara Hirase; J Luis Espinoza; Yasuyoshi Morita; Hirokazu Tanaka; Takashi Ashida; Yoichi Tatsumi; Kazuto Nishio; Itaru Matsumura
    Cancer science 113 2 660 - 673 2022年02月 
    We previously examined the utility of rituximab-bendamustine (RB) in patients with follicular lymphoma (FL) exhibiting less than optimal responses to 2 cycles of the R-CHOP chemotherapy regimen. The aim of this study was to identify molecular biomarkers that can predict prognosis in RB-treated patients in the context of the prospective cohort. We first analyzed the mutational status of 410 genes in diagnostic tumor specimens by target capture and Sanger sequencing. CREBBP, KMT2D, MEF2B, BCL2, EZH2, and CARD11 were recurrently mutated as reported before, however none was predictive for progression-free survival (PFS) in the RB-treated patients (n = 34). A gene expression analysis by nCounter including 800 genes associated with carcinogenesis and/or the immune response showed that expression levels of CD8+ T-cell markers and half of the genes regulating Th1 and Th2 responses were significantly lower in progression of disease within the 24-mo (POD24) group (n = 8) than in the no POD24 group (n = 31). Collectively, we selected 10 genes (TBX21, CXCR3, CCR4, CD8A, CD8B, GZMM, FLT3LG, CD3E, EOMES, GZMK), and generated an immune infiltration score (IIS) for predicting PFS using principal component analysis, which dichotomized the RB-treated patients into immune IIShigh (n = 19) and IISlow (n = 20) groups. The 3-y PFS rate was significantly lower in the IISlow group than in the IIShigh group (50.0% [95% CI: 27.1-69.2%] vs. 84.2% [95% CI: 58.7-94.6%], P = .0237). Furthermore, the IIS was correlates with absolute lymphocyte counts at diagnosis (r = 0.460, P = .00355). These results suggest that the T-cell-associated immune markers could be useful to predict prognosis in RB-treated FL patients. (UMIN:000 013 795, jRCT:051 180 181).
  • フルダラビン+ブスルファンを用いた同種造血幹細胞移植における重症口腔粘膜炎発症のリスク因子の解析(Risk factor of oral mucositis after allogeneic hematopoietic stem cell transplantation using FLU/BU)
    鳥畑 さやか; 江原 裕基; 助臺 美帆; 下出 孟史; 岩崎 早苗; 李 篤史; 川口 美紅; 木下 優子; 渡瀬 遂生; 濱田 傑; 金澤 仁美; 兵頭 咲紀; 宮本 あかね; 波江野 高大; 角谷 宏明; 源 周治; 口分田 貴裕; 芹澤 憲太郎; 谷口 康博; 森田 泰慶; 榎本 明史; 芦田 隆司
    日本血液学会学術集会 83回 PS - 4 2021年09月
  • Risk factor of oral mucositis after allogeneic hematopoietic stem cell transplantation using FLU/BU(和訳中)
    鳥畑 さやか; 江原 裕基; 助臺 美帆; 下出 孟史; 岩崎 早苗; 李 篤史; 川口 美紅; 木下 優子; 渡瀬 遂生; 濱田 傑; 金澤 仁美; 兵頭 咲紀; 宮本 あかね; 波江野 高大; 角谷 宏明; 源 周治; 口分田 貴裕; 芹澤 憲太郎; 谷口 康博; 森田 泰慶; 榎本 明史; 芦田 隆司
    日本血液学会学術集会 83回 PS - 4 2021年09月
  • Shinya Rai; Hiroaki Inoue; Hitoshi Hanamoto; Mitsuhiro Matsuda; Yasuhiro Maeda; Yusuke Wada; Takahiro Haeno; Yosaku Watatani; Takahiro Kumode; Chikara Hirase; J Luis Espinoza; Yasuyoshi Morita; Hirokazu Tanaka; Yoichi Tatsumi; Itaru Matsumura
    International journal of hematology 114 2 205 - 216 2021年08月 
    The aim of this trial is to evaluate the utility of rituximab-bendamustine (R-B) for untreated advanced follicular lymphoma (FL) showing non-optimal response (nOR) to R-CHOP, and to identify clinical prognostic factors for FL patients receiving R-B. Patients who failed to achieve complete response/complete response unconfirmed (CR/CRu) [nOR-group] after 2 cycles of R-CHOP subsequently received 6 cycles of R-B. The primary endpoint was the 3-year progression-free survival (PFS) rate. Secondary endpoints included determination of prognostic factors. Fifty-six patients initially received R-CHOP, 43/56 patients (76.8%) were judged as nOR, and 33/43 patients (76.7%) completed 6 cycles of R-B. At a median follow-up of 50.6 months in the nOR-group, the 3-year PFS rate was 69.0%, and the 3-year overall survival (OS) rate was 92.7%. The most common toxicities associated with R-B were grade 3-4 lymphopenia (93.0%) and neutropenia (74.4%), both of which were manageable. A multivariate analysis including dose intensity, serum soluble interleukin-2 receptor, and FL international prognostic index-2 revealed low absolute lymphocyte count (<  869/μL) at diagnosis was an independent poor prognostic factor for both PFS and OS in the R-B-treated nOR-group. This result was further confirmed in validation cohorts including R-B-treated de novo (n = 40) and relapsed (n = 49) FL patients.
  • CMML様の病型移行を来したMDSに対してアザシチジンが有効であった1例
    角谷 宏明; 口分田 貴裕; 源 周治; 頼 晋也; 森田 泰慶; 田中 宏和; 芦田 隆司; 松村 到
    臨床血液 62 3 205 - 205 (一社)日本血液学会-東京事務局 2021年03月
  • Shinya Rai; Hirokazu Tanaka; J Luis Espinoza; Takahiro Kumode; Itaru Matsumura
    Leukemia research reports 15 100256 - 100256 2021年 
    Acute myeloid leukemia (AML) is a heterogeneous disease often associated with poor prognosis. We previously showed that the localization of KIT-D816V at endolysosomes is critical to activate aberrant Akt signaling and Chlorpromazine (CPZ) perturbs the intracellular localization, leading to cell death in AML cells with KIT-D816V. We report that daily administration of CPZ, prescribed for controlling anxiety disorder in patient with AML harboring KIT-D816V, led to a dramatic reduction in AML cells. In vitro and in vivo experiments showed that CPZ inhibited the growth and survival of the patient-derived AML cells, implying potent efficacy of CPZ in AML with KIT-D816V.
  • Shinya Rai; Hirokazu Tanaka; Mai Suzuki; J. Luis Espinoza; Takahiro Kumode; Akira Tanimura; Takafumi Yokota; Kenji Oritani; Toshio Watanabe; Yuzuru Kanakura; Itaru Matsumura
    Nature Communications 11 1 4147 - 4147 2020年12月 
    © 2020, The Author(s). Mutated receptor tyrosine kinases (MT-RTKs) such as internal tandem duplication of FMS-like tyrosine kinase 3 (FLT3 ITD) and a point mutation KIT D816V are driver mutations for acute myeloid leukemia (AML). Clathrin assembly lymphoid myeloid leukemia protein (CALM) regulates intracellular transport of RTKs, however, the precise role for MT-RTKs remains elusive. We here show that CALM knock down leads to severely impaired FLT3 ITD- or KIT D814V-dependent cell growth compared to marginal influence on wild-type FLT3- or KIT-mediated cell growth. An antipsychotic drug chlorpromazine (CPZ) suppresses the growth of primary AML samples, and human CD34+CD38- AML cells including AML initiating cells with MT-RTKs in vitro and in vivo. Mechanistically, CPZ reduces CALM protein at post transcriptional level and perturbs the intracellular localization of MT-RTKs, thereby blocking their signaling. Our study presents a therapeutic strategy for AML with MT-RTKs by altering the intracellular localization of MT-RTKs using CPZ.
  • Yasuhiro Taniguchi; Naoto Takahashi; Masatomo Miura; Chikara Hirase; Sanae Sueda; J Luis Espinoza; Shinya Rai; Shoko Nakayama; Kentaro Serizawa; Takahiro Kumode; Yosaku Watatani; Yasuyoshi Morita; Hirokazu Tanaka; Itaru Matsumura
    Internal medicine (Tokyo, Japan) 59 21 2745 - 2749 2020年07月 [査読有り]
     
    We recently treated a chronic myeloid leukemia (CML) patient with liver and renal dysfunction, who was undergoing hemodialysis (HD). He was treated with 50 mg dasatinib (DAS) once daily just before HD. The maximum plasma concentration of DAS was 227 ng/mL on a non-HD day and 46.9 ng/mL on a HD day. He was subsequently treated with 200 mg bosutinib (BOS) once daily. The plasma concentration of BOS changed from 74.5 ng/mL before HD to 58.8 ng/mL after HD. Our results indicate that close monitoring of the plasma tyrosine kinase inhibitor concentrations should be considered in CML patients with organ impairment.
  • Hiroaki Inoue; Shinya Rai; Hirokazu Tanaka; J. Luis Espinoza; Maiko Komori-Inoue; Hiroaki Kakutani; Shuji Minamoto; Takahiro Kumode; Shoko Nakayama; Yasuhiro Taniguchi; Yasuyoshi Morita; Takeshi Okuda; Yoichi Tatsumi; Takashi Ashida; Itaru Matsumura
    Viruses 12 4 2020年04月 
    © 2020 by the authors. Aplastic anemia is a rare blood disease characterized by the destruction of the hematopoietic stem cells (HSC) in the bone marrow that, in the majority of cases, is caused by an autoimmune reaction. Patients with aplastic anemia are treated with immunosuppressive drugs and some of them, especially younger individuals with a donor available, can be successfully treated with hematopoietic stem cell transplantation (HSCT). We report here a rare case of post-transplant lymphoproliferative disorder (PTLD) associated with Epstein-Barr virus (EBV) reactivation in a 30-year-old female patient who underwent allogeneic HSCT for severe aplastic anemia. The PTLD, which was diagnosed 230 days after transplantation, was localized exclusively in the central nervous system (specifically in the choroid plexus) and manifested with obvious signs of intracranial hypertension. After receiving three cycles of high dose methotrexate (HD-MTX) combined with rituximab, the patient achieved a complete clinical recovery with normalization of blood cell counts, no evidence of EBV reactivation, and no associated neurotoxicity.
  • Hayato Kaida; Takahiro Kumode; Masatomo Kimura; Kazunari Ishii
    Clinical nuclear medicine 45 4 319 - 321 2020年04月 
    An 80-year-old woman experienced dyspnea. Cardiac enlargement was detected by chest radiography at a local hospital. She was admitted to our hospital, and echocardiography and CT revealed pericardial effusion and multiple tumor lesions in right atrium. F-FDG PET/CT demonstrated multiple nodular accumulations in these tumors (SUVmax, 14.5). Cytologic analysis of the pericardial fluid revealed a diffuse large B-cell lymphoma. Primary cardiac lymphoma (PCL) is rare, and there are few reports about the F-FDG PET/CT imaging features of PCLs. In high F-FDG uptake in multiple tumors in the right atrium and large pericardial effusion, a PCL should be considered.
  • Takahiro Kumode; Shinya Rai; Hirokazu Tanaka; J. Luis Espinoza; Hiroaki Kakutani; Yosaku Watatani; Shuji Minamoto; Yasuhiro Taniguchi; Shoko Nakayama; Yasuyoshi Morita; Takashi Ashida; Itaru Matsumura
    Leukemia Research Reports 14 100219 - 100219 2020年 
    © 2020 The Authors We report a case with extramedullary tumors affecting the supraclavicular region that presented as a relapse of acute myeloid leukemia (AML) with FLT3-ITD mutation after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Treatment with gilteritinib resulted in remarkable response with disappearance of both the medullary and extramedullary tumors. Subsequently, a 2nd allo-HSCT was performed in an attempt to cure his AML and complete molecular response has been sustained with gilteritinib resumption without worsening GVHD. Targeted therapy with gilteritinib for medullary and extramedullary relapse of FLT3-ITD AML could be effective and suitable as a bridging therapy for allo-HSCT.
  • Hiroaki Inoue; Shinya Rai; Hirokazu Tanaka; J. Luis Espinoza; Yosaku Watatani; Takahiro Kumode; Kentaro Serizawa; Shoko Nakayama; Yasuhiro Taniguchi; Yasuyoshi Morita; Yoichi Tatsumi; Takashi Ashida; Itaru Matsumura
    British Journal of Haematology 2020年 
    © 2020 British Society for Haematology and John Wiley & Sons Ltd Despite duodenal-type follicular lymphoma (DTFL) being morphologically, immunophenotypically and genetically indistinguishable from nodal FL (nFL), this entity typically shows a significantly better prognosis. Here, we analysed the tumour immune microenvironments of diagnostic specimens from patients with DTFL (n = 30), limited-stage FL (LSFL; n = 19) and advanced-stage FL (ASFL; n = 31). The mean number of CD8+ tumour-infiltrating lymphocytes (TILs) in the neoplastic follicles was higher in DTFL (1,827/mm2) than in LSFL (1,150/mm2) and ASFL (1,188/mm2) (P = 0·002, P = 0·002, respectively). In addition, CD8+PD1− T cells with non-exhausting phenotype were more abundant in the peripheral blood (PB) of DTFL than in LSFL and ASFL, indicating that DTFL may exhibit a better and longer-lasting T cell-mediated immune response. Moreover, whereas FOXP3+CTLA-4+ effector regulatory T cells (eTregs) were rarely observed in the neoplastic follicles of DTFL (mean: 12/mm2), they were more abundant in LSFL (78/mm2) and ASFL (109/mm2) (P = 2·80 × 10−5, P = 4·74 × 10−8, respectively), and the numbers of eTregs correlated inversely with those of CD8+ TILs (r = −0267; P = 0·018). Furthermore, DTFL showed significantly fewer circulating FOXP3hiCD45RA-CD25hi eTregs (0·146%) than ASFL (0·497%) and healthy controls (0·639%) (P = 0·0003, P = 6·79 × 10−7, respectively). These results suggest that the augmented anti-tumour immune reactions may contribute to a better prognosis on DTFL.
  • Ryoji Kato; Hidetoshi Hayashi; Keigo Sano; Kohei Handa; Takahiro Kumode; Hiroto Ueda; Tatsuya Okuno; Hisato Kawakami; Itaru Matsumura; Masatoshi Kudo; Kazuhiko Nakagawa
    Journal of Thoracic Oncology 13 12 e239 - e241 2018年12月
  • Shinya Rai; Hirokazu Tanaka; Ko Fujimoto; Takahiro Kumode; Hiroaki Inoue; Yasuhiro Taniguchi; Yasuyoshi Morita; J. Luis Espinoza; Yoichi Tatsumi; Takashi Ashida; Ryota Matsuoka; Yukie Yara Kikuti; Naoya Nakamura; Itaru Matsumura
    Cancers 10 9 2018年09月 
    © 2018 by the authors. Licensee MDPI, Basel, Switzerland. A 62-year-old male was diagnosed with chronic lymphocytic leukemia (CLL) and treated with a fludarabine-containing regimen which maintained the disease in a partial response. Nine years after diagnosis, a rapidly growing systemic lymphadenopathy was observed, and a biopsy specimen revealed the presence of typical Hodgkin/Reed-Sternberg (HRS) cells, surrounded by T-lymphocytes and CLL cells. Sequencing analysis of the germline complementary determining region 3 (CDR3) region of the immunoglobulin heavy chain (IGH) gene showed that the Hodgkin/Reed-Sternberg cells were clonally unrelated to the preexisting CLL cells and the HRS cells were composed of five different clones, leading to the molecular diagnosis of de novo lymphocyte-rich classic Hodgkin lymphoproliferative diseases (LPDs) with small lymphocytic lymphoma (SLL). As the initial treatment was neither effective for classic Hodgkin LPDs nor for SLL, Bendamustine, Rituximab (BR) was started and complete remission was achieved, which has continued for more than one year so far. BR may be a good therapeutic option for both entities without causing hematological toxicity.
  • Yasuhiro Taniguchi; Hirokazu Tanaka; Espinoza J. Luis; Kazuko Sakai; Takahiro Kumode; Keigo Sano; Kentarou Serizawa; Shinya Rai; Yasuyoshi Morita; Hitoshi Hanamoto; Kazuo Tsubaki; Kazuto Nishio; Itaru Matsumura
    International Journal of Hematology 106 5 691 - 703 2017年11月 
    © 2017, The Japanese Society of Hematology. Myeloproliferative neoplasms (MPNs), including polycythemia vera and essential thrombocythemia, are frequently associated with thrombotic complications. Prevention of thrombotic events is thus a primary aim of the current treatment for these disorders. Although it is known that microparticles (MPs), which are small vesicles released from cell membranes and circulate in the blood, directly contribute to thrombosis via their procoagulant activity, potential associations between plasma levels of MPs and the risk of thrombotic events in MPNs have not been reported. In the present study, we characterized plasma levels of MPs and assessed their potential association with the occurrence of thrombotic events in 59 patients with MPNs. Plasma levels of procoagulant MPs expressing tissue factor (TF+ MPs) were significantly higher in patients suffering thrombotic events than in patients without such events (median/μl plasma: 33.8 vs 47.2, p = 0.02). Among patients who developed thrombotic events, irrespective of patients’ blood counts, TF+ MP were significantly higher in patients without cytoreductive therapy than in those receiving cytoreductive therapy (101.2 vs. 42.5, p < 0.001). These results suggest that elevated levels of TF+ MP may be considered as a novel surrogate marker for thrombotic events in MPN patients. Further studies are needed to clarify the mechanism involved.
  • Satoru Teshigawara; Yoshinori Katada; Yuichi Maeda; Maiko Yoshimura; Eriko Kudo-Tanaka; Soichiro Tsuji; Yoshinori Harada; Masato Matsushita; Shiro Ohshima; Kotaro Watanabe; Takahiro Kumode; Yoshihiko Hoshida; Yukihiko Saeki
    Journal of Medical Case Reports 10 1 212  2016年08月 
    © 2016 The Author(s). Background: Hemophagocytic lymphohistiocytosis associated with autoimmune diseases is seen in patients with systemic juvenile idiopathic arthritis, adult-onset Still's disease, and systemic lupus erythematosus, whereas it is rarely seen in patients with dermatomyositis. In addition, central nervous system involvement with dermatomyositis is rare. To the best of our knowledge, this is the first case of hemophagocytic lymphohistiocytosis complicated by leukoencephalopathy in a patient with dermatomyositis accompanied with peripheral T-cell lymphoma. Case presentation: A 17-year-old Asian male adolescent with dermatomyositis and hemophagocytic lymphohistiocytosis that were controlled with corticosteroid therapy presented to our hospital with high fever and altered consciousness. Brain magnetic resonance imaging revealed multiple cerebral lesions. We diagnosed the central nervous system lesions as leukoencephalopathy secondary to dermatomyositis and hemophagocytic lymphohistiocytosis. Because corticosteroid and cyclophosphamide pulse therapy was ineffective, he was treated with a modified hemophagocytic lymphohistiocytosis-2004 protocol, which resulted in the disappearance of the lesions of his central nervous system. Conclusions: Our findings suggest that the hemophagocytic lymphohistiocytosis-2004 protocol including etoposide should be initiated immediately in patients with hemophagocytic lymphohistiocytosis who respond poorly to treatment for the underlying disease. Moreover, irrespective of the underlying disease, patients with hemophagocytic lymphohistiocytosis with central nervous system lesions might require bone marrow transplantation.
  • Takahiro Kumode; Ayano Fukui; Go Eguchi; Terufumi Yamaguchi; Yasuhiro Maeda
    Case Reports in Medicine 2014 793928  2014年 
    Elderly patients with secondary acute myeloid leukemia (AML) following myelodysplastic syndrome (MDS) are often medically unfit for or resistant to chemotherapy, and their prognosis is dismal. In the present paper, we reported a case of secondary leukemia following MDS in an 80-year-old male patient who was deemed unfit for chemotherapy owing to his old age and poor physical condition. Despite a high tumor burden, treatment with AZA exerted a remarkable response, leading to an immediate cytoreduction in our case. Our results suggest that AZA can be an attractive therapeutic option for elderly MDS or AML patients, offering adequate efficacy and high tolerability. © 2014 Takahiro Kumode et al.
  • Takahiro Kumode; Yasuyo Ohyama; Masaya Kawauchi; Terufumi Yamaguchi; Jun Ichi Miyatake; Yoshihiko Hoshida; Yoichi Tatsumi; Itaru Matsumura; Yasuhiro Maeda
    Leukemia and Lymphoma 54 9 1947 - 1952 2013年09月 
    Primary effusion lymphoma (PEL) is a rare type of non-Hodgkin lymphoma that usually develops in immunosuppressed patients infected with human herpes virus-8 (HHV-8) in conjunction with human immunodeficiency virus (HIV) infection. However, there are several reports of HHV-8-related HIV-negative cases and HHV-8-unrelated HIV-negative cases, mainly in immunodeficient and elderly patients. Here, we report one case of HHV-8-related HIV-negative PEL with gastric cancer (case 1) and one case of HHV-8-unrelated HIV-negative effusion-based lymphoma (case 2), both in elderly men. A 73-year-old man and a 79-year-old man were admitted because of lymphomatous effusions, and no mass was detectable in both cases. They were diagnosed as having malignant effusion lymphoma on the basis of cytological findings indicating atypical lymphoid cells and the expression of CD20 and CD79a. To detect evidence of HHV-8 infection in neoplastic cells, immunocytochemical staining for ORF73/latent nuclear antigen-1 (LNA-1) was performed. The results revealed that case 1 was ORF73-positive, and case 2 was ORF73-negative. Rituximab-based chemotherapy (R-THPCOP: rituximab, pirarubicin, cyclophosphamide, vincristine, prednisolone) was administered to both patients and complete remission was achieved in both. Compared to most HIV-positive PEL cases, these two cases showed a good response to chemotherapy. In cases of PEL, we should focus on HHV-8 infection and HIV status for determining prognosis. © 2013 Informa UK, Ltd.
  • A case of intraocular lymphoma with central nervous system involvement and high interleukin-10 levels in both vitreous humor and cerebrospinal fluids:successsful tretment with a combinnation of intravitreal,intrathecal,and systemic therapy
    宮武 淳一; 川内 超矢; 口分田 貴裕; 山口 晃史; 森田 泰慶; 辰巳 陽一; 松村 到; 前田裕弘; 大黒のぶゆき
    Int Canc Conf J 2 71 - 75 2012年10月

講演・口頭発表等

  • 三宅 義昭; 頼 晋也; 井上 宏昭; 口分田 貴裕; 谷口 康博; 中山 聖子; 森田 泰慶; Espinoza J.L.; 田中 宏和; 辰巳 陽一; 芦田 隆司; 松村 到
    日本リンパ網内系学会会誌 2019年05月 (一社)日本リンパ網内系学会
  • 井上 宏昭; 頼 晋也; 口分田 貴裕; 芹澤 憲太郎; 谷口 康博; 中山 聖子; 森田 泰慶; Luis Espinoza J.; 田中 宏和; 辰巳 陽一; 芦田 隆司; 松村 到
    日本リンパ網内系学会会誌 2019年05月 (一社)日本リンパ網内系学会
  • 芦田 隆司; 小森 舞子; 源 周治; 大山 泰世; 井上 宏昭; 口分田 貴裕; 谷口 康博; 頼 晋也; 森田 泰慶; 地守 慶亮; 前田 朋子; 中野 勝彦; 福島 靖幸; 川野 亜美; 井手 大輔; 前田 岳宏; 椿本 祐子; 藤田 往子; 金光 靖; 松村 到
    日本輸血細胞治療学会誌 2019年04月 (一社)日本輸血・細胞治療学会
  • びまん性大細胞型B細胞性リンパ腫治療中にムーコル脳塞栓を発症した1例  [通常講演]
    波江野 高大; 口分田 貴裕; 森田 泰慶; 芦田 隆司; 松村 到; 高島 康利; 木村 雅友
    臨床血液 2019年01月 (一社)日本血液学会-東京事務局
  • 末梢血幹細胞採取前のCD34細胞数測定の有用性  [通常講演]
    山田 枝里佳; 斉藤 花往里; 藤本 昂; 角谷 宏明; 岩田 吉生; 谷口 貴英; 源 周治; 大山 泰世; 口分田 貴裕; 井上 宏昭; 芹澤 憲太郎; 谷口 康博; 頼 晋也; 平瀬 主税; 森田 泰慶; 田中 宏和; 岡野 意浩; 坂田 尚己; 芦田 隆司; 松村 到
    日本アフェレシス学会雑誌 2018年10月 (一社)日本アフェレシス学会
  • CD34陽性ヒト骨髄腫幹細胞の同定と特性解析(Identification and characterization of CD34+ myeloma cell population as myeloma-initiating cells)  [通常講演]
    芹澤 憲太郎; 田中 宏和; 福井 彩乃; 藤原 亮介; 佐野 圭吾; 口分田 貴裕; 谷口 康博; 森田 泰慶; ルイス・エスピノザ; 辰巳 陽一; 芦田 隆司; 松村 到
    臨床血液 2018年09月 (一社)日本血液学会-東京事務局
  • 十二指腸型濾胞性リンパ腫は、抗腫瘍免疫により良好な予後を示す(Duodenal-type follicular lymphoma exhibits good prognosis through the increased anti-tumor immunity)  [通常講演]
    井上 宏昭; 頼 晋也; 口分田 貴裕; 芹澤 憲太郎; 谷口 康博; 中山 聖子; 森田 泰慶; ルイス・エスピノザ; 田中 宏和; 辰巳 陽一; 芦田 隆司; 松村 到
    臨床血液 2018年09月 (一社)日本血液学会-東京事務局
  • CLEC-2の発現は巨核球にバイアスした長期骨髄再建能を有する造血幹細胞集団を規定する(CLEC-2 identifies a functionally distinct subpopulation of megakaryocyte-biased HSCs)  [通常講演]
    口分田 貴裕; 田中 宏和; Espinoza J. Luis; 岩田 吉生; 佐野 圭吾; 芹澤 憲太郎; 谷口 康博; 頼 晋也; 森田 泰慶; 辰巳 陽一; 芦田 隆司; 松村 到
    臨床血液 2018年09月 (一社)日本血液学会-東京事務局
  • 自己免疫性溶血性貧血と後天性血友病A・Bを合併した脾辺縁帯リンパ腫の一例  [通常講演]
    口分田 貴裕; 三宅 義昭; 波江野 高大; 齋藤 花往里; 佐野 圭吾; 谷口 康博; 森田 泰慶; 田中 宏和; 辰巳 陽一; 芦田 隆司; 松村 到
    第16回日本臨床腫瘍学会学術総会 2018年07月 ポスター発表
  • 複数の免疫異常を合併した脾辺縁帯リンパ腫の1例  [通常講演]
    三宅 義昭; 口分田 貴裕; 波江野 高大; 森田 泰慶; 嶋田 高広; 田中 宏和; 辰巳 陽一; 芦田 隆司; 松村 到
    臨床血液 2018年02月 (一社)日本血液学会-東京事務局
  • 難治性血栓症を伴うI型クリオグロブリン血症を合併したリンパ形質細胞性リンパ腫の1例  [通常講演]
    國田 裕貴; 口分田 貴裕; 波江野 高大; 森田 泰慶; 嶋田 高広; 田中 宏和; 辰巳 陽一; 芦田 隆司; 松村 到
    臨床血液 2018年02月 (一社)日本血液学会-東京事務局
  • 鳥畑さやか; 向井隆雄; 松永和秀; 下出孟史; 三木仁美; 安本実央; 安武夏海; 下出綾那; 小森舞子; 波江野高大; 斎藤花往里; 藤本昂; 角谷宏明; 谷口貴英; 大山泰世; 井上宏昭; 口分田貴裕; 榎本明史; 濱田傑; 芦田隆司; 芦田隆司
    日本造血細胞移植学会総会プログラム・抄録集 2017年12月
  • 芦田隆司; 芦田隆司; 小森舞子; 波江野高大; 斎藤花往里; 藤本昴; 角谷宏明; 谷口貴英; 佐野圭吾; 大山泰世; 井上宏昭; 口分田貴裕; 森田泰慶; 地守慶亮; 前田朋子; 中野勝彦; 福島靖幸; 川野亜美; 井手大輔; 前田岳宏; 松村到
    日本造血細胞移植学会総会プログラム・抄録集 2017年12月
  • 小森舞子; 井上宏昭; 角谷宏明; 大山泰世; 口分田貴裕; 森田泰慶; 田中宏和; 芦田隆司; 田崎貴之; 奥田武司; 松村到
    日本造血細胞移植学会総会プログラム・抄録集 2017年12月
  • 難治性血栓症を伴うⅠ型クリオグロブリン血症を合併したリンパ形質細胞性リンパ腫の一例  [通常講演]
    國田 裕貴; 口分田 貴裕; 波江野 高大; 森田 泰慶; 嶋田 高広; 田中 宏和; 辰巳 陽一; 芦田 隆司; 松村 到
    第108回 近畿血液学地方会 2017年11月 口頭発表(一般)
  • 複数の免疫異常を合併した脾辺縁帯リンパ腫の一例  [通常講演]
    三宅 義昭; 口分田 貴裕; 波江野 高大; 森田 泰慶; 嶋田 高広; 田中 宏和; 辰巳 陽一; 芦田 隆司; 松村 到
    第108回 近畿血液学地方会 2017年11月 口頭発表(一般)
  • Hodgkin variant of Richter syndromeに対してBR療法が奏功した一例  [通常講演]
    藤本 昂; 頼 晋也; 齋藤 花往里; 口分田 貴裕; 井上 宏昭; 森田 泰慶; 田中 宏和; 嶋田 高広; 辰巳 陽一; 芦田 隆司; 松村 到
    第79回日本血液学会学術集会 2017年10月 口頭発表(一般)
  • C-type lectin-like receptor 2 specifies a functionally distinct subpopulation of megakaryocyte-biased long-term hematopoietic stem cells.  [通常講演]
    Takahiro Kumode; Hirokazu Tanaka; Ryosuke Fujiwara; Keigo Sano; Kentaro Serizawa; Yasuhiro Taniguchi; Shinya Rai; Itaru Matsumura
    The 22st European Hematology Association Congress 2017年06月 ポスター発表
  • CLEC-2 expression is a new marker for a subset of hematopoietic stem/progenitor cells that contributes to inflammation-induced emergent megakaryopoiesis.  [通常講演]
    Takahiro Kumode; Hirokazu Tanaka; Shinya Rai; Yasuhiro Taniguchi; Itaru Matsumura
    The 21st European Hematology Association Congress 2016年06月 ポスター発表
  • PROCOAGULANT MICROPARTICLE IS A NEW SURROGATE BIOMARKER FOR THROMBOTIC EVENTS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS  [通常講演]
    Y. Taniguchi; H. Tanaka; T. Kumode; S. Rai; I. Matsumura
    HAEMATOLOGICA 2016年06月 FERRATA STORTI FOUNDATION
  • 芹澤憲太郎; 森田泰慶; 口分田貴裕; 田中宏和; 山田枝里佳; 芦田隆司; 芦田隆司; 松村到
    日本輸血細胞治療学会誌 2016年04月
  • 宮武淳一; 岩田吉生; 谷口貴英; 源周治; 大山泰世; 川内超矢; 佐野圭吾; 口分田貴裕; 芹澤憲太郎; 谷口康博; 頼晋也; 金井良高; 平瀬主税; 森田泰慶; 田中宏和; 辰巳陽一; 芦田隆司; 松村到
    日本造血細胞移植学会総会プログラム・抄録集 2015年02月
  • 口分田貴裕; 岩田吉夫; 谷口貴秀; 源周治; 大山泰世; 佐野圭吾; 川内超矢; 芹澤憲太郎; 谷口康博; 頼晋也; 金井良高; 平瀬主税; 森田泰慶; 田中宏和; 宮武淳一; 辰巳陽一; 芦田隆司; 松村到
    日本造血細胞移植学会総会プログラム・抄録集 2015年02月
  • 星田義彦; 勅使川原悟; 片田圭宣; 由良亜紀子; 片山理人; 吉村麻衣子; 渡邊あかね; 田中枝里子; 辻聡一郎; 松下正人; 大島至郎; 佐伯行彦; 口分田貴裕; 山口晃史; 前田裕弘
    日本病理学会会誌 2014年03月
  • 後藤孝和; 江口剛; 口分田貴裕; 山口晃史; 前田裕弘
    臨床血液 2014年02月
  • 前田裕弘; 岩田吉生; 江口剛; 口分田貴裕; 山口晃史
    日本エイズ学会誌 2013年11月
  • Effects of anti-CCR4 antibodies for adult T-cell leukemia and anti-CCR4 antibodies for adult T-cell leukemia and a risk for viral infection  [通常講演]
    江口 剛; 口分田 貴裕; 山口 晃史; 松村 到; 前田裕弘
    第75回 日本血液学会学術集会 2013年10月 札幌 第75回 日本血液学会学術集会
  • A useful treatment with azacitidine for ellderly MDS/AML patients  [通常講演]
    口分田 貴裕; 江口 剛; 山口 晃史; 松村 到; 前田裕弘
    第75回日本血液学会学術集会 2013年10月 札幌 第75回日本血液学会学術集会
  • Results of gemcitabine therapy for related of refractory Non-Hodgkin’slymphoma in one institute  [通常講演]
    芹澤 憲太郎; 森田 泰慶; 谷口 康博; 川内 超矢; 江口 剛; 江本 正克; 金井 良高; 賴 晋也; 平瀨 主税; 田中 宏和; 口分田 貴裕; 宮武 淳一; 辰巳 陽一; 芦田 隆司; 松村 到
    第75回日本血液学会学術集会 2013年10月 札幌 第75回日本血液学会学術集会
  • 岩田吉生; 口分田貴裕; 江口剛; 山口晃史; 勅使川原悟; 片田圭宣; 星田義彦; 前田裕弘
    臨床血液 2013年08月
  • 山本健太; 山口晃史; 大山泰世; 口分田貴裕; 前田裕弘; 星田義彦
    臨床血液 2013年02月
  • A case of HHV-8-associated HIV-negative primary effusion lymphomawith gastric cancer  [通常講演]
    口分田 貴裕; 川内 超矢; 宮武 淳一; 辰巳 陽一; 松村 到; Shigeaki Fujita; 前田裕弘
    第74回日本血液学会学術集会 2012年10月 京都 第74回日本血液学会学術集会
  • 松本知之; 口分田貴裕; 川内超矢; 宮武淳一; 前田裕弘
    臨床血液 2012年08月
  • C-MYC/IGH融合遺伝子を伴うDLBCLにR-CODOX-M/IVAC療法が奏効した1例  [通常講演]
    川内 超矢; 口分田 貴裕; 山口 晃史; 金井 良高; 宮武 淳一; 松村 到; 大山 泰世; 前田裕弘; 藤田茂樹
    第197回日本内科学会近畿地方会 2012年06月 兵庫 第197回日本内科学会近畿地方会
  • 前田裕弘; 口分田貴裕; 川内超矢; 宮武淳一
    日本抗加齢医学会総会プログラム・抄録集 2012年06月
  • 芹澤 憲太郎; 川西 一信; 大山 泰世; 尾嶋 真由子; 井上 宏昭; 口分田 貴裕; 江本 正克; 谷口 康博; 金井 良高; 賴 晋也; 笹川淳; 平瀨 主税; 山口 晃史; 森田 泰慶; 田中 宏和; 嶋田 高広; 辰巳 陽一; 芦田 隆司; 松村 到
    第34回日本造血細胞移植学会総会 2012年02月 大阪 第34回日本造血細胞移植学会総会
  • 芦田隆司; 川野亜美; 山田枝里佳; 井手大輔; 菅野知恵美; 加藤祐子; 椿本祐子; 伊藤志保; 峯佳子; 藤田往子; 井上宏昭; 口分田貴裕; 芹澤憲太郎; 江本正克; 平瀬主税; 山口晃史; 森田泰慶; 川西一信; 辰巳陽一; 松村到
    日本造血細胞移植学会総会プログラム・抄録集 2012年02月
  • Analysis of iron overload in patients with transfusion-dependent hematological diseases  [通常講演]
    芦田 隆司; 川野亜美; 山田枝里佳; 井手大輔; 菅野知恵美; 加藤祐子; 椿本祐子; 伊藤志保; 峯 佳子; 藤田往子; 金光 靖; 森嶋祥之; 大山 泰世; 尾嶋 真由子; 井上 宏昭; 口分田 貴裕; 芹澤 憲太郎; 江本 正克; 谷口 康博; 田中 宏和; 金井 良高; 賴 晋也; 笹川 淳; 平瀨 主税; 山口 晃史; 森田 泰慶; 嶋田 高広; 川西 一信; 辰巳 陽一; 松村 到
    第73回日本血液学会学術集会 2011年10月 名古屋 第73回日本血液学会学術集会
  • 頼晋也; 松田光弘; 口分田貴裕; 井上宏昭; 川内超矢; 江本正克; 芹澤憲太郎; 金井良高; 山口晃史; 森田泰慶; 嶋田高広; 宮武淳一; 辰巳陽一; 芦田隆司; 前田裕弘; 松村到
    日本造血細胞移植学会総会プログラム・抄録集 2011年
  • A young case diagnosed concomitantly as B-CLL and B-cell lymphoma  [通常講演]
    賴 晋也; 辰巳 陽一; 口分田 貴裕; 井上 宏昭; 川内 超矢; 江口 剛; 大山 雄一; 山口 晃史; 森田 泰慶; 嶋田 高広; 宮武 淳一; 芦田 隆司; 前田 裕弘; 松村 到; 松田 光弘
    第72回 日本血液学会学術集会 2010年09月 横浜 第72回 日本血液学会学術集会
  • 急性混合性白血病を発症し、同種骨髄移植にて寛解維持するも一年後骨腫瘤病変にて再発し再移植した症例  [通常講演]
    江口 剛; 山口 晃史; 口分田 貴裕; 井上 宏昭; 川内 超矢; 大山 雄一; 賴 晋也; 森田 泰慶; 嶋田 高広; 川西 一信; 宮武 淳一; 辰巳 陽一; 芦田 隆司; 前田 裕弘; 松村 到; 金丸 昭久; 佐野 徹明
    第20回 南近畿血液病フォーラム 2010年07月 大阪 第20回 南近畿血液病フォーラム
  • 頼晋也; 辰巳陽一; 口分田貴裕; 大山雄一; 金井良高; 平瀬主税; 山口晃史; 森田泰慶; 嶋田高広; 川西一信; 宮武淳一; 芦田隆司; 前田裕弘; 松村到; 松田光弘; 金丸昭久
    日本リンパ網内系学会会誌 2010年05月
  • 口分田貴裕; 頼晋也; 辰巳陽一; 大山雄一; 金井良高; 平瀬主税; 山口晃史; 森田泰慶; 嶋田高広; 川西一信; 宮武淳一; 芦田隆司; 前田裕弘; 松村到; 金丸昭久
    日本リンパ網内系学会会誌 2010年05月
  • 化学療法に抵抗性で急激な転帰をとったmyeloid/NK-cell precursor acute leukaemiaの一例  [通常講演]
    口分田 貴裕; 頼 晋也; 辰巳 陽一; 大山 雄一; 金井 良高; 平瀬 主税; 山口 晃史; 森田 泰慶; 嶋田 高広; 川西 一信; 宮武 淳一; 芦田 隆司; 前田 裕弘; 松村 到; 金丸 昭久
    日本リンパ網内系学会会誌 2010年05月 (一社)日本リンパ網内系学会

MISC

  • 口分田貴裕; 頼晋也; 波江野高大; 角谷宏明; 源周治; 綿谷陽作; 芹澤憲太郎; 谷口康博; 森田泰慶; 田中宏和; 芦田隆司; 松村到 日本造血細胞移植学会総会プログラム・抄録集 43rd 2021年
  • 谷口康博; 平瀬主税; 芦田隆司; 波江野高大; 角谷宏明; 源周治; 綿谷陽作; 口分田貴裕; 芹澤憲太郎; 頼晋也; 森田泰慶; 田中宏和; 辰巳陽一; 松村到 日本造血細胞移植学会総会プログラム・抄録集 43rd 2021年
  • 角谷宏明; 口分田貴裕; 源周治; 頼晋也; 森田泰慶; 田中宏和; 芦田隆司; 松村到 臨床血液 62 (3) 2021年
  • 谷口康博; 芦田隆司; 森田泰慶; 平瀬主税; 頼晋也; 中山聖子; 芹澤憲太郎; 口分田貴裕; 井上宏昭; 岩田吉男; 谷口貴英; 源周治; 角谷宏明; 藤本昂; 小森舞子; 波江野高大; 三宅義昭; 辰巳陽一; 田中宏和; 松村到 日本造血細胞移植学会総会プログラム・抄録集 42nd 2020年
  • 鳥畑さやか; 江原裕基; 助臺美帆; 下出孟史; 金澤仁美; 守屋実央; 安武夏海; 兵頭咲紀; 小森舞子; 源周治; 綿谷陽作; 井上宏昭; 口分田貴裕; 谷口康博; 頼晋也; 森田泰慶; 増田智丈; 榎本明史; 濱田傑; 芦田隆司; 芦田隆司 日本造血細胞移植学会総会プログラム・抄録集 42nd 2020年
  • 難治性血栓症を伴うI型クリオグロブリン血症を合併したリンパ形質細胞性リンパ腫の1例
    國田 裕貴; 口分田 貴裕; 波江野 高大; 森田 泰慶; 嶋田 高広; 田中 宏和; 辰巳 陽一; 芦田 隆司; 松村 到 臨床血液 59 (2) 239 -240 2018年02月
  • 複数の免疫異常を合併した脾辺縁帯リンパ腫の1例
    三宅 義昭; 口分田 貴裕; 波江野 高大; 森田 泰慶; 嶋田 高広; 田中 宏和; 辰巳 陽一; 芦田 隆司; 松村 到 臨床血液 59 (2) 240 -240 2018年02月
  • 化学療法に抵抗性で急激な転帰をとったmyeloid/NK-cell precursor acute leukaemiaの一例
    口分田 貴裕; 頼 晋也; 辰巳 陽一; 大山 雄一; 金井 良高; 平瀬 主税; 山口 晃史; 森田 泰慶; 嶋田 高広; 川西 一信; 宮武 淳一; 芦田 隆司; 前田 裕弘; 松村 到; 金丸 昭久 日本リンパ網内系学会会誌 50 106 -106 2010年05月
  • 特異な臨床経過を示した若年発症慢性リンパ性白血病の一例
    頼 晋也; 辰巳 陽一; 口分田 貴裕; 大山 雄一; 金井 良高; 平瀬 主税; 山口 晃史; 森田 泰慶; 嶋田 高広; 川西 一信; 宮武 淳一; 芦田 隆司; 前田 裕弘; 松村 到; 松田 光弘; 金丸 昭久 日本リンパ網内系学会会誌 50 123 -123 2010年05月

共同研究・競争的資金等の研究課題

その他のリンク

researchmap



Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.